Literature DB >> 2290026

Circulating osteocalcin in primary biliary cirrhosis following liver transplantation and during treatment with ciclosporin.

R G Watson1, L Coulton, J A Kanis, M Lombard, R Williams, J Neuberger, E Elias.   

Abstract

Circulating osteocalcin, a non-collagen bone protein is considered a useful indirect index of turnover. Osteocalcin levels were measured by radioimmunoassay in 57 female patients with primary biliary cirrhosis (PBC) from two centres, 52 normal female controls, 11 female patients following liver transplantation for PBC and seven female patients with PBC treated with Ciclosporin. Serum levels were significantly less in the PBC group (median 10 ng/ml) compared to normals (median 15 ng/ml: p less than 0.001). Patients with PBC treated with Ciclosporin had significantly higher levels than untreated patients (median 23 ng/ml: p less than 0.001). Levels also increased significantly following transplantation when all patients were receiving Ciclosporin (median 40 ng/ml: p less than 0.001). The results suggest that the abnormal bone metabolism of PBC is significantly altered by Ciclosporin and liver transplantation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2290026     DOI: 10.1016/0168-8278(90)90221-c

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  6 in total

1.  Pamidronate and osteoporosis prevention in liver transplant recipients.

Authors:  Pietra Pennisi; Andrea Trombetti; Emiliano Giostra; Gilles Mentha; René Rizzoli; Carmelo E Fiore
Journal:  Rheumatol Int       Date:  2006-08-31       Impact factor: 2.631

Review 2.  Bone disease after liver transplantation.

Authors:  M S Losowsky; S H Hussaini
Journal:  Gut       Date:  1996-10       Impact factor: 23.059

3.  Bone loss after liver transplantation is not prevented by cyclical etidronate, calcium and alphacalcidol. The Liver Transplant Group, Groningen.

Authors:  S C Riemens; A Oostdijk; J J van Doormaal; C J Thijn; G Drent; D A Piers; E W Groen; L Meerman; M J Slooff; E B Haagsma
Journal:  Osteoporos Int       Date:  1996       Impact factor: 4.507

Review 4.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

5.  Calcitonin and bisphosphonates treatment in bone loss after liver transplantation.

Authors:  M A Valero; C Loinaz; L Larrodera; M Leon; E Moreno; F Hawkins
Journal:  Calcif Tissue Int       Date:  1995-07       Impact factor: 4.333

Review 6.  Osteoporosis after solid organ and bone marrow transplantation.

Authors:  Adi Cohen; Elizabeth Shane
Journal:  Osteoporos Int       Date:  2003-08-08       Impact factor: 4.507

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.